Compare STRIDES PHARMA SCIENCE with Jubilant Pharmova - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs JUBILANT PHARMOVA - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE JUBILANT PHARMOVA STRIDES PHARMA SCIENCE/
JUBILANT PHARMOVA
 
P/E (TTM) x 42.1 14.6 288.3% View Chart
P/BV x 2.0 2.7 72.1% View Chart
Dividend Yield % 0.2 0.5 45.3%  

Financials

 STRIDES PHARMA SCIENCE   JUBILANT PHARMOVA
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
JUBILANT PHARMOVA
Mar-19
STRIDES PHARMA SCIENCE/
JUBILANT PHARMOVA
5-Yr Chart
Click to enlarge
High Rs1,147898 127.7%   
Low Rs642618 104.0%   
Sales per share (Unadj.) Rs317.2572.0 55.5%  
Earnings per share (Unadj.) Rs7.836.2 21.7%  
Cash flow per share (Unadj.) Rs25.159.5 42.1%  
Dividends per share (Unadj.) Rs2.004.50 44.4%  
Dividend yield (eoy) %0.20.6 37.6%  
Book value per share (Unadj.) Rs274.3301.9 90.8%  
Shares outstanding (eoy) m89.50159.28 56.2%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.81.3 212.8%   
Avg P/E ratio x114.020.9 545.1%  
P/CF ratio (eoy) x35.712.7 280.4%  
Price / Book Value ratio x3.32.5 130.0%  
Dividend payout %25.512.4 205.2%   
Avg Mkt Cap Rs m80,058120,694 66.3%   
No. of employees `0002.52.4 104.9%   
Total wages/salary Rs m4,34119,260 22.5%   
Avg. sales/employee Rs Th11,325.838,120.6 29.7%   
Avg. wages/employee Rs Th1,731.48,058.4 21.5%   
Avg. net profit/employee Rs Th280.12,414.3 11.6%   
INCOME DATA
Net Sales Rs m28,39491,108 31.2%  
Other income Rs m941357 263.2%   
Total revenues Rs m29,33491,466 32.1%   
Gross profit Rs m3,96517,390 22.8%  
Depreciation Rs m1,5403,709 41.5%   
Interest Rs m1,9622,198 89.3%   
Profit before tax Rs m1,40311,840 11.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-2,802 15.6%   
Tax Rs m973,268 3.0%   
Profit after tax Rs m7025,770 12.2%  
Gross profit margin %14.019.1 73.2%  
Effective tax rate %6.927.6 25.1%   
Net profit margin %2.56.3 39.0%  
BALANCE SHEET DATA
Current assets Rs m24,83645,848 54.2%   
Current liabilities Rs m18,99320,897 90.9%   
Net working cap to sales %20.627.4 75.1%  
Current ratio x1.32.2 59.6%  
Inventory Days Days7157 125.0%  
Debtors Days Days11351 222.6%  
Net fixed assets Rs m34,28965,498 52.4%   
Share capital Rs m895159 561.8%   
"Free" reserves Rs m23,65147,930 49.3%   
Net worth Rs m24,54648,089 51.0%   
Long term debt Rs m15,51342,429 36.6%   
Total assets Rs m65,437114,685 57.1%  
Interest coverage x1.76.4 26.9%   
Debt to equity ratio x0.60.9 71.6%  
Sales to assets ratio x0.40.8 54.6%   
Return on assets %4.16.9 58.6%  
Return on equity %2.912.0 23.8%  
Return on capital %6.912.4 55.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,69712,422 126.4%   
Fx outflow Rs m73517,227 4.3%   
Net fx Rs m14,962-4,805 -311.4%   
CASH FLOW
From Operations Rs m1,87111,215 16.7%  
From Investments Rs m5,826-10,118 -57.6%  
From Financial Activity Rs m-10,1576,574 -154.5%  
Net Cashflow Rs m-2,6157,612 -34.4%  

Share Holding

Indian Promoters % 27.7 45.6 60.7%  
Foreign collaborators % 0.0 3.5 -  
Indian inst/Mut Fund % 37.8 8.7 434.5%  
FIIs % 8.6 21.2 40.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 25.9 21.1 122.7%  
Shareholders   56,241 23,815 236.2%  
Pledged promoter(s) holding % 0.0 15.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare STRIDES PHARMA SCIENCE With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (4QFY20); Net Profit Up 358.8% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, JUBILANT LIFE SCIENCES has posted a net profit of Rs 3 bn (up 358.8% YoY). Sales on the other hand came in at Rs 24 bn (up 0.2% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

JUBILANT LIFE SCIENCES Announces Quarterly Results (3QFY20); Net Profit Down 24.0% (Quarterly Result Update)

Feb 1, 2020 | Updated on Feb 1, 2020

For the quarter ended December 2019, JUBILANT LIFE SCIENCES has posted a net profit of Rs 2 bn (down 24.0% YoY). Sales on the other hand came in at Rs 23 bn (down 2.6% YoY). Read on for a complete analysis of JUBILANT LIFE SCIENCES's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY20); Net Profit Up 2778.7% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 2 bn (up 2778.7% YoY). Sales on the other hand came in at Rs 7 bn (down 2.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Worst Sector in the Market(Fast Profits Daily)

May 11, 2021

The worst sector in the stock market according to the charts.

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


May 14, 2021 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 5-YR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS